MYCN and neuroblastoma: Patients with MYCN-amplified NB showed a similar probability for 1-year OS and a tendency towards a decreased 1-year EFS probability compared with patients without MYCN-amplified NB (OS: 42% [95% CI 8–76] versus 43% [95% CI 17–69], p = 0.396; EFS: 0% [95% CI 0.0–0.0] versus 38% [95% CI 0.12–0.65], p = 0.162).